Modulation Therapeutics, Inc.

Morgantown, WV

UEI
FPRRYGJGEHB1
CAGE
6G0X1
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
64 Medical Center Dr, Morgantown, WV 26505, USA
Founded
2011
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
"targeted AC-225-radiopharmaceutical for metastatic uveal melanoma"period of performance: 9/18/2017 - 9/17/2019 HHSN261201700035C National Cancer Institute (NIH) $1,999,987
Sbir topic 339 HHSN261201500067C National Cancer Institute (NIH) $299,336

Grant awards

Award Agency Obligated Awarded
MTI-301 a SCD1 inhibitor for the treatment of nash R41DK131705 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $344,919
Modulation of cancer induced immune suppression via inhibition of SCD1 R44CA272064 National Cancer Institute (NIH) $5,001,229
Development of mitoneet agonists for the treatment of stroke R41NS110070 National Institute of Neurological Disorders and Stroke (NIH) $258,700
Development of an a MC1R selective companion diagnostic imaging probe R43CA235992 National Cancer Institute (NIH) $248,155
Development of pegylated MTI-101 for the treatment of relapsed myeloma R44CA221554 National Cancer Institute (NIH) $2,434,274

Latest 5 listed here. See the rest on GovTribe.

Quick answers

Is Modulation Therapeutics, Inc. registered in SAM.gov?

Yes. Modulation Therapeutics, Inc.'s SAM.gov registration is active through August 9, 2027.

What is Modulation Therapeutics, Inc.'s most recent federal award?

Modulation Therapeutics, Inc.'s most recent federal grant award is MTI-301 a SCD1 inhibitor for the treatment of nash (R41DK131705), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on May 1, 2023.

On GovTribe

See Modulation Therapeutics, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login